Oncology Medications Policy — Coverage and Prior Authorization for Primary and Supportive Cancer Therapies
Customize your policy alerts
Sign up for all evicore policy alerts
Know when evicore releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization, coverage, and clinical governance for FDA‑approved oncology medications used for direct cancer treatment and specified supportive care therapies under Cigna plans administered by eviCore.
No material clinical or coverage changes in this revision.
Coverage Criteria for Oncology Medications
Primary cancer treatment coverage
Covered when ONE of the following is met
Includes FDA‑approved biosimilars as acceptable substitutes
Supportive care medication coverage
Covered when ONE of the following is met
All listed supportive classes recognized; prior authorization required unless the drug or class is listed as exempted in Section 2a
Medication uses that are not associated with the direct treatment of cancer or cancer-related symptoms are outside the scope of this policy. This exclusion encompasses any indication or clinical use where the medication is not being used to treat cancer itself or to manage symptoms directly attributable to the cancer or its treatment.
All oncology medication uses related to stem cell or bone marrow transplantation — including but not limited to mobilization, harvest, transplant procedures, associated supportive care, and management of graft‑versus‑host disease — are explicitly outside the scope of this policy and are governed by separate transplant‑specific policies or protocols.
Coverage determinations under this policy depend on the terms of the member’s applicable benefit plan and any applicable laws or regulations. Treatments that are inconsistent with a member’s specific benefit plan terms, or that lack required authorization or supporting documentation, may be deemed not covered or not medically necessary per the applicable benefit plan document. In the event of a conflict, the customer’s benefit plan document supersedes this policy.
Coding and Reference Resources
| No codes listed |
Provider Actions and Authorization Requirements
Prior authorization required for oncology and supportive drugs
Prior authorization is required for all drugs used for direct cancer treatment and for the listed supportive oncology medication classes unless the drug or class is listed as exempted in Section 1a (Primary Treatment) or Section 2a (Supportive Medications).
Check Cigna prescription & MedOnc drug lists
Providers must consult Cigna’s Prescription Drug Lists and the Cigna MedOnc Master Drug List, as these plan-specific lists may dictate utilization management rules (for example, step edits) that apply to the requested medication.
Include benefit plan, legal basis, and clinical documentation
When requesting authorization, providers should reference the member’s applicable benefit plan document, any relevant laws or regulations, and include clinical documentation that supports medical necessity for the requested oncology medication.
- Member’s applicable benefit plan document in effect on date of service
- Relevant federal or state laws and regulations (if applicable)
- Clinical records supporting diagnosis, indication, prior treatments, and rationale for the requested drug
Denial risk if plan terms or prior authorization are missing
Coverage determinations depend on the terms of the applicable benefit plan, any applicable laws/regulations, and the specific facts of the case; claims inconsistent with plan terms or lacking required prior authorization are at risk of denial and conflicts defer to the customer’s benefit plan.
- Claims lacking required prior authorization may be denied.
- If the customer’s benefit plan conflicts with this policy, the benefit plan document supersedes the policy.
Definitions and Scope Terms
Background and Guiding Principles
This policy aligns coverage for oncology medications with FDA indications and with recommendations in the NCCN Guidelines (Categories 1, 2A, 2B). FDA‑approved agents (including recognized biosimilars) used for direct cancer treatment and specified supportive care classes are governed here; exceptions to NCCN guidance may be considered based on individual clinical circumstances and additional references. Where a customer’s benefit plan or law conflicts with these sources, the benefit plan or law controls the coverage determination.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.